Gregory Smull, MD
Pulmonary Disease · Tampa, FLNPI 1093780520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 27.5% of the total. Reporting peaked in 2020 at $263 and has fallen 75.8% since, to $64 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 48 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$249
- AstraZeneca$139
- Boehringer Ingelheim$67
- Jazz Pharmaceuticals Inc.$58
- Regeneron Healthcare Solutions, Inc.$51
- Baxter Healthcare$44
- plus $297 from 13 others
What the payments were for
- Food & beverage$904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $249 |
| AstraZeneca | 8 | $139 |
| Boehringer Ingelheim | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Baxter Healthcare | 2 | $44 |
| Bayer | 2 | $43 |
| Amgen | 2 | $30 |
| Insmed, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $25 |
| CSL Behring | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| UCB, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Vapotherm Inc | 1 | $12 |
| Ambu Inc. | 1 | $12 |
How this compares
$904 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Tampa
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- Michael AlvarezTampa$202K
- Nirav PatelTampa$105K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.